NO20092455L - Modulering av prostaglandin/syklooksygenase-metabolske baner - Google Patents
Modulering av prostaglandin/syklooksygenase-metabolske banerInfo
- Publication number
- NO20092455L NO20092455L NO20092455A NO20092455A NO20092455L NO 20092455 L NO20092455 L NO 20092455L NO 20092455 A NO20092455 A NO 20092455A NO 20092455 A NO20092455 A NO 20092455A NO 20092455 L NO20092455 L NO 20092455L
- Authority
- NO
- Norway
- Prior art keywords
- metabolic pathways
- cyclooxygenase
- prostaglandin
- modulation
- inflammation
- Prior art date
Links
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 title abstract 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 title abstract 2
- 230000037353 metabolic pathway Effects 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- AWSUSADYFDCYML-KUPUPYBPSA-N (z)-7-[(1s,5r)-5-[(e)-oct-1-enyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound CCCCCC\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O AWSUSADYFDCYML-KUPUPYBPSA-N 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86787306P | 2006-11-30 | 2006-11-30 | |
| GB0623971A GB0623971D0 (en) | 2006-11-30 | 2006-11-30 | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| PCT/GB2007/004584 WO2008065408A2 (en) | 2006-11-30 | 2007-11-29 | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092455L true NO20092455L (no) | 2009-08-14 |
Family
ID=39381924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092455A NO20092455L (no) | 2006-11-30 | 2009-06-29 | Modulering av prostaglandin/syklooksygenase-metabolske baner |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100137270A1 (https=) |
| EP (2) | EP2097079B1 (https=) |
| JP (1) | JP2010511028A (https=) |
| KR (1) | KR20090086272A (https=) |
| AU (1) | AU2007327011A1 (https=) |
| CA (1) | CA2670957A1 (https=) |
| HR (1) | HRP20120687T1 (https=) |
| IL (1) | IL199013A0 (https=) |
| MX (1) | MX2009005753A (https=) |
| NO (1) | NO20092455L (https=) |
| PL (1) | PL2097079T3 (https=) |
| TW (1) | TWI414298B (https=) |
| WO (1) | WO2008065408A2 (https=) |
| ZA (1) | ZA200903584B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
| GB0523550D0 (en) | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
| WO2013120851A1 (en) * | 2012-02-13 | 2013-08-22 | Mach-3D Sàrl | Method for sharing emotions through the creation of three-dimensional avatars and their interaction through a cloud-based platform |
| US9328060B2 (en) | 2013-10-18 | 2016-05-03 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics |
| JP6917631B2 (ja) * | 2016-02-15 | 2021-08-11 | 学校法人近畿大学 | 抗不安作用を有する医薬組成物および加工食品 |
| WO2023060107A1 (en) * | 2021-10-05 | 2023-04-13 | University Of South Florida | Compositions and uses thereof for treatment of neurological disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7100213A (en) * | 1971-01-08 | 1972-07-11 | 1,2,3,4-tetrahydrocarbazole derivs - anti-inflammatories | |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| US5451600A (en) * | 1994-04-19 | 1995-09-19 | Hoffmann-La Roche Inc. | Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors |
| EP0906090A1 (en) * | 1996-03-15 | 1999-04-07 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
| WO2000006560A1 (en) * | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| GB0003524D0 (en) * | 2000-02-15 | 2000-04-05 | Btg Int Ltd | Cytoprotective steroids (II) |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| AU780173B2 (en) | 2000-08-25 | 2005-03-03 | Michael John Till | Sampling device |
| WO2002069977A1 (en) * | 2001-03-01 | 2002-09-12 | Hollis-Eden Pharmaceuticals, Inc. | Use of certain steroids for treatment of blood cell deficiencies |
| SE0100857D0 (sv) * | 2001-03-13 | 2001-03-13 | Tomas Hagstroem | Treatment of tumors |
| GB2378898A (en) * | 2001-08-14 | 2003-02-26 | Hunter Fleming Ltd | Prophylactic and therapeutic use of hydroxysteroids |
| FR2829697B1 (fr) * | 2001-09-14 | 2004-03-19 | Mayoly Spindler Lab | Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin |
| GB0403889D0 (en) * | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| US20070231373A1 (en) * | 2004-04-28 | 2007-10-04 | Hunter-Fleming Limited | Transdermal Steriod for Formulation |
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
| US20060234993A1 (en) * | 2005-04-13 | 2006-10-19 | Eric Marchewitz | Use of androstane derivatives for enhancing physical performance |
-
2007
- 2007-11-29 WO PCT/GB2007/004584 patent/WO2008065408A2/en not_active Ceased
- 2007-11-29 CA CA002670957A patent/CA2670957A1/en not_active Abandoned
- 2007-11-29 JP JP2009538785A patent/JP2010511028A/ja active Pending
- 2007-11-29 AU AU2007327011A patent/AU2007327011A1/en not_active Abandoned
- 2007-11-29 EP EP07870407A patent/EP2097079B1/en active Active
- 2007-11-29 MX MX2009005753A patent/MX2009005753A/es active IP Right Grant
- 2007-11-29 KR KR1020097013708A patent/KR20090086272A/ko not_active Ceased
- 2007-11-29 EP EP09012181A patent/EP2147673A1/en not_active Withdrawn
- 2007-11-29 HR HRP20120687TT patent/HRP20120687T1/hr unknown
- 2007-11-29 US US12/516,772 patent/US20100137270A1/en not_active Abandoned
- 2007-11-29 PL PL07870407T patent/PL2097079T3/pl unknown
- 2007-11-30 TW TW096145663A patent/TWI414298B/zh not_active IP Right Cessation
-
2009
- 2009-05-22 ZA ZA2009/03584A patent/ZA200903584B/en unknown
- 2009-05-27 IL IL199013A patent/IL199013A0/en unknown
- 2009-06-29 NO NO20092455A patent/NO20092455L/no not_active Application Discontinuation
-
2012
- 2012-08-03 US US13/566,136 patent/US20130023504A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130023504A1 (en) | 2013-01-24 |
| WO2008065408A2 (en) | 2008-06-05 |
| WO2008065408A9 (en) | 2011-03-03 |
| US20100137270A1 (en) | 2010-06-03 |
| KR20090086272A (ko) | 2009-08-11 |
| CA2670957A1 (en) | 2008-06-05 |
| TWI414298B (zh) | 2013-11-11 |
| WO2008065408A3 (en) | 2008-11-20 |
| MX2009005753A (es) | 2009-09-28 |
| HRP20120687T1 (hr) | 2012-09-30 |
| AU2007327011A1 (en) | 2008-06-05 |
| EP2097079A2 (en) | 2009-09-09 |
| EP2147673A1 (en) | 2010-01-27 |
| ZA200903584B (en) | 2010-11-24 |
| TW200831108A (en) | 2008-08-01 |
| EP2097079B1 (en) | 2012-06-27 |
| IL199013A0 (en) | 2010-02-17 |
| JP2010511028A (ja) | 2010-04-08 |
| PL2097079T3 (pl) | 2012-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092455L (no) | Modulering av prostaglandin/syklooksygenase-metabolske baner | |
| Oliveri | Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation | |
| CY1123253T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν αναστολεα του sglt2, εναν αναστολεα της dpp-iv και προαιρετικα εναν επιπλεον αντιδιαβητικο παραγοντα και χρησεις αυτης | |
| Mak et al. | Galangin’s potential as a functional food ingredient | |
| EA201000321A1 (ru) | Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола | |
| BRPI0911520A2 (pt) | novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de angiogênese. | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| NO20083572L (no) | Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer | |
| CL2007003874A1 (es) | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio | |
| MX385777B (es) | Derivado de biarilo como agonista de gpr120. | |
| WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
| BRPI0716555A2 (pt) | mÉtodos para prever a probabilidade de que um paciente É um candidato para tratamento com uma droga de ret responderÁ ao citado tratamento, e para tratar um paciente, iniciador direto mutante de arms, e, kit diagnàstico | |
| WO2006108582A3 (en) | Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis | |
| EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
| PT2056805E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular | |
| Sung et al. | Ulinastatin suppresses lipopolysaccharide-induced prostaglandin E2 synthesis and nitric oxide production through the downregulation of nuclear factor‑κB in BV2 mouse microglial cells | |
| WO2005113016A3 (en) | Modulation of glucose-6-phosphatase translocase expression | |
| BRPI0607003A2 (pt) | forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda | |
| PT1828151E (pt) | Derivados de malonamida como inibidores de gama-secretase para o tratamento da doença de alzheimer | |
| WO2008070311A3 (en) | Gene expression profiling of parkinson's disease | |
| WO2008030532A3 (en) | Substituted oxazole ketone modulators of fatty acid amide hydrolase | |
| WO2007070355A3 (en) | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes | |
| WO2008048691A3 (en) | Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders | |
| BRPI0607976A2 (pt) | composição farmacêutica e uso de uma composição | |
| EP1765364A4 (en) | PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |